SandboxAQ
- Biotech or pharma, therapeutic R&D
- CMO, CRO
SandboxAQ’s AI- and physics-based in silico drug discovery platform, AQBioSim, enables faster, more precise identification and optimization of small molecule and biologic candidates across a wide range of therapeutic areas. Since spinning out of Alphabet in 2022, we’ve raised $950 million from top-tier investors to scale our technology and impact in from target ID through hit finding, lead optimization, and clinical candidate nomination. Today, we support over 18+ active external pipelines in partnership with leading pharmaceutical, biotech, and academic institutions.
Address
Palo AltoCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}